A.R.T. Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

A.R.T. Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-53,224	Closed	-$192K	–	1800
2019 Q1	$192K	Buy	+53,224	New	+$231K	0.01%	1085
2018 Q3	–	Sell	-78,979	Closed	-$335K	–	1876
2018 Q2	$335K	Buy	+78,979	New	+$398K	0.01%	1071
2017 Q1	–	Sell	-17,900	Closed	-$128K	–	1860
2016 Q4	$128K	Buy	17,900 +2,900	+19%	+$23.4K	0.01%	1122
2016 Q3	$140K	Sell	15,000 -56,515	-79%	-$469K	0.05%	535
2016 Q2	$451K	Buy	71,515 +32,111	+81%	+$207K	0.02%	834
2016 Q1	$217K	Sell	39,404 -120,000	-75%	-$451K	0.01%	1143
2015 Q4	$889K	Buy	159,404 +142,915	+867%	+$945K	0.04%	620
2015 Q3	$139K	Sell	16,489 -10,272	-38%	-$174K	0.01%	1219
2015 Q2	$404K	Buy	+26,761	New	+$386K	0.01%	1077

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

A.R.T. Advisors's PETX Position: Q2 2019 in Review

A.R.T. Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 53,224 shares — an estimated $192K sold.

A.R.T. Advisors first reported a position in PETX in Q2 2015 and held it in 9 quarters. The position peaked at $889K in Q4 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

A.R.T. Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 53,224 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $192K.
A.R.T. Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
A.R.T. Advisors's Aratana Therapeutics, Inc. position peaked at $889K in Q4 2015.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.